Jonathan M. Weiss, Ph.D.
Jonathan M. Weiss, Ph.D.
Staff Scientist

Dr. Weiss is investigating the mechanisms whereby combinations of cytokines and other immune-modulating drugs, such as anti-CD40, result in the eradication of tumors. Principally, he is interested in understanding the mechanisms of leukocyte recruitment into the tumor microenvironment and the responses by these tumor-infiltrating leukocytes as they relate to tumor progression and/or metastases.

Areas of Expertise
1) immunotherapy, 2) leukocytes

Contact Info

Jonathan M. Weiss, Ph.D.
Center for Cancer Research
National Cancer Institute
Building 560; Room 31-18
Frederick, MD 21702-1201
(301) 846-5394
WeissJ@ncifcrf.gov

Combination-based immunotherapies may more effectively activate cells of both innate and adaptive immune responses. Using an orthotopic mouse model of renal cell carcinoma (RENCA), I am investigating the mechanisms whereby combinations of cytokines and other immune-modulating drugs, such as anti-CD40, result in the eradication of tumors. Principally, I am interested in understanding the mechanisms of leukocyte recruitment into the tumor microenvironment and the responses by these tumor-infiltrating leukocytes as they relate to tumor progression and/or metastases.

Selected Publications
  1. Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ.
    PLoS ONE. 9: e85398, 2014. [ Journal Article ]
  2. Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.
    Int J Cancer. 132: 41900, 2013. [ Journal Article ]
  3. Jiang Q, Weiss JM, Wiltrout RH.
    Oncoimmunology. 1: 115-117, 2012. [ Journal Article ]
  4. Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.
    Blood. 119: 3073-83, 2012. [ Journal Article ]
  5. Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.
    PLoS ONE. 7: e33303, 2012. [ Journal Article ]

Jonathan Weiss received his Ph.D. from Albert Einstein College of Medicine in 1998, where he studied the role of chemokines and cellular adhesion molecules in mediating leukocyte transmigration across the human blood-brain barrier with Dr. Joan Berman. He was then a postdoc with Dr. Leslie Parise at the University of North Carolina Chapel Hill, where he studied the molecular regulation of platelet aggregation. He continued his postdoctoral training at the University of Virginia with Dr. Alan Horwitz, where he utilized a high-throughput screening strategy to screen for novel molecular regulators of cell adhesion and migration. After that, he spent three years as a research scientist at MaxCyte, Inc., a biotechnology company focused on the electroporation of DNA and siRNA into primary hematopoietic cells. His research there demonstrated the enhanced anti-tumor response through ex vivo loading of dendritic cells with whole tumor lysate. In 2005, he joined the Cancer and Inflammation Program where his current research focuses on the immunotherapy of renal cell carcinoma by combination cytokine therapy.

Research

Combination-based immunotherapies may more effectively activate cells of both innate and adaptive immune responses. Using an orthotopic mouse model of renal cell carcinoma (RENCA), I am investigating the mechanisms whereby combinations of cytokines and other immune-modulating drugs, such as anti-CD40, result in the eradication of tumors. Principally, I am interested in understanding the mechanisms of leukocyte recruitment into the tumor microenvironment and the responses by these tumor-infiltrating leukocytes as they relate to tumor progression and/or metastases.

Publications

Selected Publications
  1. Chen X, Yang Y, Zhou Q, Weiss JM, Howard OZ, McPherson JM, Wakefield LM, Oppenheim JJ.
    PLoS ONE. 9: e85398, 2014. [ Journal Article ]
  2. Okayama H, Saito M, Oue N, Weiss JM, Stauffer J, Takenoshita S, Wiltrout RH, Hussain SP, Harris CC.
    Int J Cancer. 132: 41900, 2013. [ Journal Article ]
  3. Jiang Q, Weiss JM, Wiltrout RH.
    Oncoimmunology. 1: 115-117, 2012. [ Journal Article ]
  4. Tietze JK, Wilkins DE, Sckisel GD, Bouchlaka MN, Alderson KL, Weiss JM, Ames E, Bruhn KW, Craft N, Wiltrout RH, Longo DL, Lanier LL, Blazar BR, Redelman D, Murphy WJ.
    Blood. 119: 3073-83, 2012. [ Journal Article ]
  5. Chan T, Back TC, Subleski JJ, Weiss JM, Ortaldo JR, Wiltrout RH.
    PLoS ONE. 7: e33303, 2012. [ Journal Article ]

Biography

Jonathan Weiss received his Ph.D. from Albert Einstein College of Medicine in 1998, where he studied the role of chemokines and cellular adhesion molecules in mediating leukocyte transmigration across the human blood-brain barrier with Dr. Joan Berman. He was then a postdoc with Dr. Leslie Parise at the University of North Carolina Chapel Hill, where he studied the molecular regulation of platelet aggregation. He continued his postdoctoral training at the University of Virginia with Dr. Alan Horwitz, where he utilized a high-throughput screening strategy to screen for novel molecular regulators of cell adhesion and migration. After that, he spent three years as a research scientist at MaxCyte, Inc., a biotechnology company focused on the electroporation of DNA and siRNA into primary hematopoietic cells. His research there demonstrated the enhanced anti-tumor response through ex vivo loading of dendritic cells with whole tumor lysate. In 2005, he joined the Cancer and Inflammation Program where his current research focuses on the immunotherapy of renal cell carcinoma by combination cytokine therapy.